Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Therapix Biosciences Ltd ADR TRPXY

Therapix Biosciences Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several innovative immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The operating segments of the group are Development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the Company's operation); and Pain clinic


OTCPK:TRPXY - Post by User

Post by easyas123on Dec 11, 2018 9:08am
96 Views
Post# 29095931

Release

ReleaseReuters BRIEF-Therapix Biosciences Provides Update Regarding Fsd Acquisition 12/11/2018 8:57:42 AM Therapix Biosciences Ltd: * THERAPIX BIOSCIENCES PROVIDES UPDATE REGARDING FSD ACQUISITION * THERAPIX BIOSCIENCES LTD - IT WAS AGREED THAT TERMS OF LOI ARE TO BE SUPERSEDED BY A DEFINITIVE AGREEMENT * THERAPIX BIOSCIENCES LTD - TRANSACTION IS STILL BEING NEGOTIATED * THERAPIX BIOSCIENCES LTD - COMPANY AND FSD ARE STILL IN NEGOTIATIONS AND FSD WISHES TO MODIFY CERTAIN MATERIAL TERMS OF TRANSACTION Source text for Eikon: Further company coverage: This is not the update we wanted. Maybe this will spark some interest from another party, that would be ideal.
<< Previous
Bullboard Posts
Next >>